F. Mennini

Pharmacoeconomics:Open Access Using Real-World Data to Estimate the Social Security Costs of Retinal Diseases: Results from the Observatory on Legal Blindness

R. Migliorini, F. Mennini, Trabucco Aurilio, 2019 .

PIN11 - HPV9-RELATED DISEASES: THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM IN ITALY

A. Marcellusi, C. Nardone, R. Migliorini, 2018, Value in Health.

PCV84 REHOSPITALIZATION DUE TO SUBSEQUENT CARDIOVASCULAR EVENTS IN SECONDARY PREVENTION PATIENTS TREATED WITH LIPID LOWERING THERAPIES IN ITALY

A. Maggioni, P. Sciattella, M. Belfiore, 2019, Value in Health.

PRICING FOR MULTI INDICATION MEDICINES: A DISCUSSION WITH ITALIAN EXPERTS

G. Racagni, G. Nocentini, C. Jommi, 2022, Pharmadvances.

PCN159 The Economic Analysis of Social Security Costs Cancer-Related in Italy

C. Nardone, R. Migliorini, V. Sciannaméa, 2020 .

PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND

B. Malcolm, A. Marcellusi, J. May, 2019, Value in Health.

Cost of poor adherence to anti-hypertensive therapy in five European countries

G. Staffiero, R. Schmieder, A. Gray, 2015, The European Journal of Health Economics.

PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY

B. Malcolm, A. Marcellusi, C. Bini, 2019, Value in Health.